Premium
FDA approves Abilify pill with sensor that tracks compliance
Publication year - 2017
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30264
Subject(s) - pill , food and drug administration , drug labeling , medicine , aripiprazole , psychiatry , package insert , advertising , internet privacy , drug , schizophrenia (object oriented programming) , pharmacology , computer science , business
The U.S. Food and Drug Administration last month approved the first drug in the United States with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, for acute treatment of manic and mixed episodes associated with bipolar I disorder, and for use as an add‐on treatment for depression in adults.